Matches in DBpedia 2015-10 for { ?s ?p "Allozyne is a clinical stage biotechnology company headquartered in Seattle’s biotech and high tech innovation corridor. Its lead product AZ01 is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week.Allozyne was founded in 2005 by Caltech researchers and was incubated by Accelerator Corporation."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- Allozyne abstract "Allozyne is a clinical stage biotechnology company headquartered in Seattle’s biotech and high tech innovation corridor. Its lead product AZ01 is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week.Allozyne was founded in 2005 by Caltech researchers and was incubated by Accelerator Corporation.".